Management reports breakeven adjusted EBITDA while expanding AI and sequencing capacity.
The company reported better-than-expected fiscal fourth-quarter metrics.
Twist Bioscience (TWST) delivered earnings and revenue surprises of +25.58% and +2.63%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Twist Bioscience recently introduced Twist MRD Express, a high throughput custom panel platform that can deliver personalized molecular residual disease research panels with up to 10,000 probes, rapid turnaround starting within one day, and bioinformatics and ecommerce support for oncology workflows. The launch connects Twist Bioscience’s silicon based DNA synthesis capacity directly to liquid biopsy and MRD research demand, as the firm aims to support scalable supply chains for cancer assay...
Twist Bioscience has seen its stock price move sharply in recent years. This puts a spotlight on a simple but important question for investors who care about valuation: Is the current share price sensibly linked to the sales the company is generating today and what those sales might reasonably support over time? Over the past 3 years, Twist Bioscience has delivered a share price return of about 7x. That raises the stakes on whether that move is grounded in its revenue base rather than just...
This is the newest page. Registered accounts read further back.